FDA approves expanded label for Keytruda for locally advanced cutaneous squamous cell carcinoma that is not curable by surgery or radiation – Merck Inc.
Merck has announced that the FDA has approved an expanded label for Keytruda, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of patients with locally advanced cutaneous squamous… read more.